Plant Summary
TCMBank_ID: | TCMBANKHE005961 |
YEM_ID: | YEM-928 |
ID: | TCMBANKHE005961/YEM-928 |
植物拉丁名: |
|
功能与主治: | Treatment of collapse with cold limbs and faint pulse, impotence, frigidity, precordial and abdominal pain with cold sensation, vomiting and diarrhea or edema accompanied by aversion to cold and cold extremities, colds in patients with yang deficiency, chronic arthritis due to attack of cold and damp (marked by persistent severe joint pain, fixed in place and accompanied by heaviness sensation and numbness)./1. Aconitine is a physiologically active component, and becomes aconine after hydrolized. The toxicity of aconine is lower than aconitine.2. The prepared products may dilate the blood vessels of lower limbs and coronary artery, and increase coronary flow.3. Aconine and hypaconitine are analgesics and sedatives.4. Acclerating the metabolism of lipids and cholesterol.5. LD50 of aconitine is 0.295mg/kg in mice hypodermally and that of the decoction of prepared aconite is 17.42g/kg in mice orally.6. Its components, higenamine and coryneine chloride exert a significant cardiotonic effect. |
药用植物名: | 炮附子|乌头 |
药名: | 乌头 |
来源: | 云南民族药物志:第五卷 |
药用部位: | Aconitum carmichaeli Debx |
使用民族: | 阿昌族/布依族/傣族/德昂族/回族/景颇族/傈僳族/苗族/水族/彝族 |
药味: | Extreme Hot; Pungent; Sweet |
经络: | Spleen; Heart; Kidney |
毒性: | Toxic |
临床特征: | 1. Aconitine is a physiologically active component, and becomes aconine after hydrolized. The toxicity of aconine is lower than aconitine.2. The prepared products may dilate the blood vessels of lower limbs and coronary artery, and increase coronary flow |
治疗类型: | 温里 |
TCM_ID_id: | 6723 |
TCMSP_id: | 540 |
化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
---|
TCMBANKIN001590 | coryneine chloride | C[N+](C)(C)CCC1=CC(=C(C=C1)O)O.[I-] | |||
TCMBANKIN047645 | aconitine | aconitine ; Aconitine | C34H47NO11 | 646 | C1([H])([H])[C@]([H])(OC([H])([H])[H])[C@]2([C@@]([H])([C@@]([H])([C@]3(OC(C([H])([H])[H])=O)[C@@]([H])([C@@]([H])(OC(=O)c4c([H])c([H])c([H])c([H])c4[H])[C@]([C@]([H])(OC([H])([H])[H])[C@]3([H])O[H])( O[H])C5([H])[H])[C@]25[H])[C@]6([H])OC([H])([H])[H])N(C([H])([H])C([H])([H])[H])C7([H])[H])[C@@]6([H])[C@@]7(C([H])([H])OC([H])([H])[H])[C@]1([H])O[H] |
TCMBANKIN048200 | hypaconitine | Hypaconitine; aconitine alkaloids | C33H45NO10 | 616 | C1([H])([H])[C@]([H])(OC([H])([H])[H])[C@]2([C@@]([H])([C@@]([H])([C@]3(OC(C([H])([H])[H])=O)[C@@]([H])([C@@]([H])(OC(=O)c4c([H])c([H])c([H])c([H])c4[H])[C@]([C@]([H])(OC([H])([H])[H])[C@]3([H])O[H])( O[H])C5([H])[H])[C@]25[H])[C@]6([H])OC([H])([H])[H])N(C([H])([H])[H])C7([H])[H])[C@@]6([H])[C@@]7(C([H])([H])OC([H])([H])[H])C1([H])[H] |
TCMBANKIN049264 | mesaconitine | C33H45NO11 | 632 | C1([H])([H])[C@]([H])(OC([H])([H])[H])[C@]2([C@@]([H])([C@@]([H])([C@]3(OC(C([H])([H])[H])=O)[C@@]([H])([C@@]([H])(OC(=O)c4c([H])c([H])c([H])c([H])c4[H])[C@]([C@]([H])(OC([H])([H])[H])[C@]3([H])O[H])( O[H])C5([H])[H])[C@]25[H])[C@]6([H])OC([H])([H])[H])N(C([H])([H])[H])C7([H])[H])[C@@]6([H])[C@@]7(C([H])([H])OC([H])([H])[H])[C@]1([H])O[H] | |
TCMBANKIN058638 | higenamine | UNII-6016M93W29; CHEBI:27751; (R)-Norcoclaurine; 6,7-Dihydroxy-(1R)-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline; 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-, (1R)-; (1R)-1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol; 6016M93W29; SCHEMBL5898913; AX8328517; DTXSID90331552; (+)-HIGENAMINE; UNII-TBV5O16GAP component WZRCQWQRFZITDX-CQSZACIVSA-N; CHEMBL501778; 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-, (R)-; C06347; (R)-(+)-Higenamine; (+)-Demethylcoclaurine; 106032-53-5; BDBM50242856; AC1L9ACA; (1R)-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol; AK00743742; (R)-1-(4-Hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol; Higenamine, (+)-; ZINC896041; demethylcoclaurine; demetahyl coclaurine | C16H17NO3 | 271.31 g/mol | C1CNC(C2=CC(=C(C=C21)O)O)CC3=CC=C(C=C3)O |
疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
---|
靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
---|